Alexion Pharmaceuticals, Inc. (ALXN)

[surf1944]

6:31AM Alexion Pharma: FDA grants priority review for sBLA for Soliris as a treatment for patients with Atypical Hemolytic Uremic Syndrome (ALXN) 47.42 : Co announces that the FDA granted the co's request for Priority Review of its supplemental Biologics License Application) for Soliris as a treatment for patients with atypical Hemolytic Uremic Syndrome. A Priority Review designation is given to drugs that may offer major advances in treatment, or provide a treatment where no adequate therapy exists. If approval is granted, co anticipates that Soliris would be available for U.S. patients with aHUS in the fourth quarter of 2011.